December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Jessica M. Stempel on Aza-Ven +/- Pembro in older AML
Dec 11, 2024, 17:22

Jessica M. Stempel on Aza-Ven +/- Pembro in older AML

Amer Zeidan, Associate Professor of Medicine at Yale University, shared a post on X:

Dr. Jessica M. Stempel fantastically presented our investigator-initiated randomized phase 2 trial of aza-ven +/- Pembro in older AMLsm, ASH24 which was unfortunately negative but showed importance of using ELN2024 for risk stratification and feasibility of central MRD in primary endpoint. IMG.”

Jessica M. Stempel

Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center. Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.

More posts featuring Amer Zeidan.